uploads///Imbruvica

A Performance Overview of JNJ’s Imbruvica, Velcade, and Zytiga

By

Oct. 26 2018, Updated 9:00 a.m. ET

Imbruvica’s revenue trends

Johnson & Johnson’s (JNJ) Imbruvica generated revenue of $705.0 million in the third quarter compared to $512.0 million in the third quarter of 2017, reflecting a ~37.7% YoY (year-over-year) rise.

In the third quarter, in the US and international markets, Johnson & Johnson’s Imbruvica generated revenues of $334.0 million and $371.0 million, respectively, reflecting rises of ~45.2% and 31.6% YoY.

Imbruvica’s net revenue in the first nine months of 2018 totaled $1.9 billion compared to $1.4 billion in the same period of the previous year, reflecting ~39.5% YoY growth. In the marketplace, Imbruvica’s peers include Gilead Sciences’ (GILD) Zydelig and AbbVie’s (ABBV) Venclexta. In the second quarter, Zydelig reported revenue of $39.0 million.

Article continues below advertisement

Zytiga’s revenue trends

In the third quarter, Zytiga reported revenue of $958.0 million compared to $669.0 million in the third quarter of 2017, reflecting ~43.2% YoY growth. In the US and international markets, in the third quarter, Zytiga generated revenues of $527.0 million and $431.0 million, respectively, compared to $352.0 million and $317.0 million, respectively, in the third quarter of 2017, reflecting ~49.7% and ~36.0% YoY growth.

Zytiga generated net revenue of $2.7 billion in the first nine months of 2018 compared to $1.8 billion in the same period of the previous year, reflecting ~55.0% YoY growth.

Velcade’s revenue trends

Johnson & Johnson commercializes Velcade in the international markets, while Takeda Pharmaceutical (TKPYY) commercializes Velcade in the US market.

Velcade’s revenue remained nearly flat in the third quarter compared to the third quarter of 2017. In the third quarter, Velcade generated revenue of $271.0 million compared to $273.0 million in the third quarter of 2017.

Johnson & Johnson generated revenue of $864.0 million in the first nine months of 2018 from the sales of Velcade compared to $843.0 million in the same period of the previous year, reflecting ~2.5% YoY growth.

The revenue rises of Imbruvica, Zytiga, and Velcade are expected to significantly boost Johnson & Johnson’s revenue growth. Johnson & Johnson, Gilead Sciences, and AbbVie make up ~10.64%, ~3.62%, and ~2.67% of the Health Care Select Sector SPDR ETF (XLV).

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.